Novo Nordisk taps new chief for American operations

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Novo Nordisk taps new chief for American operations

Jesper Høiland has been appointed as president of Novo Nordisk's ($NVO) North American affiliate. Høiland was previously Novo Nordisk's head of international operations, where he oversaw all of the company's operations outside of Europe, China, Japan, Korea and North America. Høiland replaces Jerzy Gruhn, who has served in the role since 2008 and will now lead the company's European business. In the first 6 months of 2013, Novo's North American region comprised 46% of the company's total reported sales. Release

Novo Nordisk
Jesper Høiland became president of Novo Nordisk's North American affiliate.


TetraLogic

J. Kevin Buchi has joined TetraLogic as CEO.

Biotech

TetraLogic brought on several new members of its executive team, including J. Kevin Buchi as its president and CEO, Pete Meyers as its chief financial officer and Lesley Russell as its chief operating officer. Release

San Diego-based Epic Sciences has appointed Murali Prahalad as president and CEO. Prahalad was formerly vice president of corporate strategy at Life Technologies ($LIFE). Release

Dallas-based Gradalis has appointed Phillip B. Maples executive vice president and chief technical officer. Prior to this appointment, Maples served as vice president of technical operations at Gradalis and has held previous executive positions at Baxter Healthcare ($BAX), US Oncology, CellExSys, and Chromos Molecular Systems. Release

Algeta appointed Andreas Menrad as the company's chief scientific officer. Before Algeta, Menrad was a general manager at Genzyme. Release

Ambrx of San Diego has appointed Peter Kiener as chief scientific officer. Kiener is cofounder of Zyngenia and was the executive vice president and global head of biologics research and development at MedImmune. Release

ParagonRx tapped Stephen Sun, a former FDA official, to be the company's chief medical officer. Release

John Richard joined Biota Pharmaceuticals' board of directors, replacing former board member Jeffrey Errington. Release

NeoStem picked up Robert Dickey to be the company's chief financial officer. Dickey has held leading positions at such companies as Hemispherx ($HEB) and StemCyte. Release

> K. Peter Hirth joined KineMed's board of directors. Release

Xymogen appointed Chris Mason to be the company's marketing director. Release

Princeton, NJ-based Advaxis ($ADXS) has appointed Daniel O'Connor, formerly executive vice president, to the position of president and CEO. Dr. James Patton has also been elected as nonexecutive chairman of the board. Release

Belgium's Galapagos has appointed David Smith CEO of its service division and a member of the Galapagos Executive Committee. Release

Histogenics, based in Waltham, MA, has added Stephen Kennedy, previously with Genzyme, as senior vice president of manufacturing, operations and supply chain, and Vladimir Scerbin, previously with Covidien ($COV), as vice president of clinical affairs. Release

Boonton, NJ-based Enteris BioPharma has hired Timothy J. Saxon as vice president of business development. Most recently, Saxon was an associate partner with Alacrita Consulting. Release

CalciMedica, of La Jolla, CA, has appointed Michael Dunn as senior vice president of corporate development. Dunn joins CalciMedica from Biocept, where he served as senior vice president of corporate development. Release

Richard Sherman has been appointed to Morris Plains, NJ-based Immunomedics' ($IMMU) board of directors. Previously, Sherman spent more than a decade as deputy general counsel of SmithKline Beckman (now GlaxoSmithKline). Release

Pharma

Murray Goldberg has been elected to Edminster, NJ-based Aerie Pharmaceuticals' board of directors. Mr. Goldberg has had a successful career in corporate finance and banking, and he has served as Chief Financial Officer of Regeneron Pharmaceuticals ($REGN) since 1995. Release

London-based SkyePharma has appointed Andrew Derodra chief financial officer and an executive director. Derodra joins SkyePharma from Tate & Lyle, where he has been group vice president of finance and control since 2011. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.